Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16796536 | 1.00 | NPC1 (0.44) | NPC1ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL16796556 | 1.00 | NPC1 (0.44) | NPC1ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL1993399 | 0.93 | NPC1 (0.43) | NPC1ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL1993403 | 0.93 | NPC1 (0.43) | NPC1ALDH1A1GAAKDM4EHPGD | |
| SCHEMBL18119915 | 0.85 | NPC1 (0.40) | NPC1ALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL19491672 | 0.85 | NPC1 (0.40) | NPC1ALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL18119916 | 0.85 | NPC1 (0.40) | NPC1ALDH1A1KDM4EHPGDMEN1 | |
| SCHEMBL12695301 | 0.84 | BACE1 (0.36) | NPC1ALDH1A1KDM4EHPGDSSTR4 | |
| SCHEMBL17177098 | 0.84 | KCNH2 (0.45) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL3274414 | 0.83 | AOC3 (0.44) | SSTR4MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111491930-B | Substituted Indole Compounds Useful as TLR Inhibitors | 百时美施贵宝公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| EP-4051388-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-09-07 | — | — | EP | disclosed |
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | HOFFMANN-LA ROCHE INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-B1 | PROCESS FOR THE PREPARATION OF A CHIRAL 2-(4-AMINOPHENYL)MORPHOLINE | HOFFMANN LA ROCHE (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-3080284-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. Hoffmann-La Roche AG (CH) | 2016-10-19 | — | — | EP | disclosed |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | HOFFMANN-LA ROCHE INC. (US) | 2016-10-06 | — | — | US | disclosed |
| WO-2015086495-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-06-18 | — | — | WO | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043232-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS, INC. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2486037-A2 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | Afraxis, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044535-A2 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10337039-B2 | Process for the preparation of chiral 2-aryl morpholines | TAAR1, TAAR5, TACR2 | NPC1 3349/4885ALDH1A1 400/4885GAA 4025/4885 |
| US-20160289718-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 2-ARYL MORPHOLINES | TAAR1, TAAR5, TACR2 | NPC1 3349/4885ALDH1A1 400/4885GAA 4025/4885 |
| US-20120270866-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | NPC1 1738/4885ALDH1A1 2756/4885GAA 2342/4885 |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | NPC1 1738/4885ALDH1A1 2756/4885GAA 2342/4885 |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | NPC1 3133/4885ALDH1A1 1870/4885GAA 2344/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | NPC1 3428/4885ALDH1A1 1936/4885GAA 2340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.